The drug lowered levels of two key inflammation signals in the blood, showing it reduces body-wide inflammation even when cholesterol doesn’t change.

14

Pro

0

Against

Evidence from Studies

Supporting (1)

14

Community contributions welcome

14

Atorvastatin Improves Plaque Stability in ApoE-Knockout Mice by Regulating Chemokines and Chemokine Receptors

Cohort Study

Animal

2014

The study gave mice a common cholesterol drug called atorvastatin and found it lowered inflammation markers in their blood — even though their cholesterol didn’t drop — which is exactly what the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Atorvastatin Improves Plaque Stability in ApoE-Knockout Mice by Regulating Chemokines and Chemokine Receptors

Score: 14

DOI: 10.1371/journal.pone.0097009

Similar Assertions

The drug lowered the activity of enzymes that break down the structural fibers in plaques, which may help keep plaques from rupturing.

0

14

79%

The drug reduced the number of inflammatory immune cells inside the artery plaques by nearly 40%, which also made the plaques less fatty and changed their collagen structure.

14

0

78%

Atorvastatin helps the support cells (pericytes) wrap around new blood vessels in plaques more tightly, making them stronger and less likely to leak.

15

0

78%

In mice prone to clogged arteries, a daily dose of atorvastatin made the dangerous, rupture-prone plaques much less common—even though the overall blockage didn’t get smaller.

14

0

77%

The drug lowered the levels of chemical signals (MCP-1 and CX3CL1) that attract immune cells to plaques, and also reduced the number of receptors on blood cells that respond to those signals.

14

0

75%